Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.

BACKGROUND Mortality from sepsis and septic shock remains high. Results of trials on intravenous immunoglobulins (IVIG) as adjunctive therapy for sepsis have been conflicting. This is an update of a Cochrane review that was originally published in 1999 and updated in 2002 and 2010. OBJECTIVES To estimate the effects of IVIG as adjunctive therapy in patients with bacterial sepsis or septic shock on mortality, bacteriological failure rates, and duration of stay in hospital. SEARCH METHODS We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 6), MEDLINE (1966 to December 2012), and EMBASE (1988 to December 2012). We contacted investigators in the field for unpublished data. The original search was performed in 1999 and updated in 2002 and 2008. SELECTION CRITERIA We included randomized controlled trials comparing IVIG (monoclonal or polyclonal) with placebo or no intervention in patients of any age with bacterial sepsis or septic shock. DATA COLLECTION AND ANALYSIS Two authors independently assessed the studies for inclusion and undertook methodologic quality assessment and data abstraction. We conducted pre-specified subgroup analyses by type of immunoglobulin preparation. MAIN RESULTS We included 43 studies that met our inclusion criteria in this updated review out of 88 potentially eligible studies. The studies included a large polyclonal IVIG trial in neonates that was concluded in 2011 and classified as ongoing in the 2010 version of this review. Pooled analysis of polyclonal and monoclonal IVIG was not done due to clinical heterogeneity. Subgroup analysis of 10 polyclonal IVIG trials (n = 1430) and seven trials on IgM-enriched polyclonal IVIG (n = 528) showed significant reductions in mortality in adults with sepsis compared to placebo or no intervention (relative risk (RR) 0.81; 95% confidence interval (CI) 0.70 to 0.93 and RR 0.66; 95% CI 0.51 to 0.85, respectively). Subgroup analysis of polyclonal IVIG in neonates, which now includes the recently concluded large polyclonal IVIG trial, showed no significant reduction in mortality for standard IVIG (RR 1.00; 95% CI 0.92 to 1.08; five trials, n = 3667) and IgM-enriched polyclonal IVIG (RR 0.57; 95% CI 0.31 to 1.04; three trials, n = 164). Sensitivity analysis of trials with low risk of bias showed no reduction in mortality with polyclonal IVIG in adults (RR 0.97; 95% CI 0.81 to 1.15; five trials, n = 945) and neonates (RR 1.01; 95% CI 0.93 to 1.09; three trials, n = 3561). Mortality was not reduced among patients (eight trials, n = 4671) who received anti-endotoxin antibodies (RR 0.99; 95% CI 0.91 to1.06) while anti-cytokines (nine trials, n = 7893) demonstrated a marginal reduction in mortality (RR 0.92; 95% CI 0.86 to 0.97). AUTHORS' CONCLUSIONS Polyclonal IVIG reduced mortality among adults with sepsis but this benefit was not seen in trials with low risk of bias. Among neonates with sepsis, there is sufficient evidence that standard polyclonal IVIG, as adjunctive therapy, does not reduce mortality based on the inclusion of the large polyclonal IVIG trial on neonates. For Ig-M enriched IVIG, the trials on neonates and adults were small and the totality of the evidence is still insufficient to support a robust conclusion of benefit. Adjunctive therapy with monoclonal IVIGs remains experimental.

[1]  A. Ohlsson,et al.  Intravenous immunoglobulin for suspected or proven infection in neonates. , 2015, The Cochrane database of systematic reviews.

[2]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 , 2013, Critical care medicine.

[3]  A. Aynalı,et al.  The Effects of Adjuvant Immunoglobulin M-Enriched Immunoglobulin Therapy on Mortality Rate and Renal Function in Sepsis-Induced Multiple Organ Dysfunction Syndrome: Retrospective Analysis of Intensive Care Unit Patients , 2012, The Journal of international medical research.

[4]  A E Ades,et al.  An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. , 2012, Health technology assessment.

[5]  B. Farrell,et al.  Treatment of neonatal sepsis with intravenous immune globulin. , 2011, The New England journal of medicine.

[6]  Cheng Cheng Tan,et al.  Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study , 2011, BMJ : British Medical Journal.

[7]  D. Annane.  Improving clinical trials in the critically ill: Unique challenge—Sepsis , 2009, Critical care medicine.

[8]  D. Cooper,et al.  The Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. , 2008, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[9]  A. Nierhaus,et al.  Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock * , 2007, Critical care medicine.

[10]  R. Schmieder,et al.  Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study * , 2007, Critical care medicine.

[11]  A. Delaney,et al.  Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta‐analysis * , 2007, Critical care medicine.

[12]  B. Hutton,et al.  Meta-analysis: Intravenous Immunoglobulin in Critically Ill Adult Patients with Sepsis , 2007, Annals of Internal Medicine.

[13]  Yongqiang Wang,et al.  Treatment of septic thrombocytopenia with immunoglobulin , 2006 .

[14]  W. Hiddemann,et al.  IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial* , 2006, Critical care medicine.

[15]  S. Kurtoğlu,et al.  Exchange transfusion or intravenous immunoglobulin therapy as an adjunct to antibiotics for neonatal sepsis in developing countries: a pilot study , 2006, Annals of tropical paediatrics.

[16]  A. El-Nawawy,et al.  Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. , 2005, Journal of tropical pediatrics.

[17]  S. Ünal,et al.  Epidemiology and outcome of sepsis in a tertiary-care hospital in a developing country , 2005, Epidemiology and Infection.

[18]  V. Sundararajan,et al.  The microbiology and outcome of sepsis in Victoria, Australia , 2005, Epidemiology and Infection.

[19]  J. Rello,et al.  EFFECTS OF HIGH-DOSE OF INTRAVENOUS IMMUNOGLOBULIN AND ANTIBIOTICS ON SURVIVAL FOR SEVERE SEPSIS UNDERGOING SURGERY , 2005, Shock.

[20]  Steven B. Johnson,et al.  Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels* , 2004, Critical care medicine.

[21]  P. Gøtzsche,et al.  Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  A. Ohlsson,et al.  Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. , 2004, The Cochrane database of systematic reviews.

[23]  A. Norrby-Teglund,et al.  Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive care medicine.

[25]  Steven B. Johnson,et al.  Multicenter evaluation of a human monoclonal antibody to Entero-bacteriaceae common antigen in patients with Gram-negative sepsis , 2003, Critical care medicine.

[26]  A. Norrby-Teglund,et al.  Intravenous Immunoglobulin Adjunctive Therapy in Sepsis, with Special Emphasis on Severe Invasive Group A Streptococcal Infections , 2003, Scandinavian journal of infectious diseases.

[27]  K. Venetsanou,et al.  The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view , 2002, Critical care.

[28]  Y. Seyhun,et al.  The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830] , 2002, Critical care.

[29]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[30]  K. Werdan,et al.  Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[31]  J. A. Kruse,et al.  E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.

[32]  N. Nagesh,et al.  Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. , 1999, Indian pediatrics.

[33]  D. Pittet,et al.  Impact of immunomodulating therapy on morbidity in patients with severe sepsis. , 1999, American journal of respiratory and critical care medicine.

[34]  M. Sturzenegger,et al.  Adverse Effects of Intravenous Immunoglobulin Therapy , 1999, Drug safety.

[35]  R. Kaul,et al.  Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  J. Wittes,et al.  Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  S. Nasraway,et al.  Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock , 1998, The Lancet.

[38]  W. Hop,et al.  Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  S. Opal,et al.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.

[40]  C. Natanson,et al.  Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. , 1997, Critical care medicine.

[41]  K. Werdan,et al.  POLYVALENT IMMUNE GLOBULINS: 18 , 1997 .

[42]  K. Werdan,et al.  Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis. , 1997, Chest.

[43]  B. Pollock,et al.  Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis. , 1997, Pediatrics.

[44]  C H Schmid,et al.  Large trials vs meta-analysis of smaller trials : How do their results compare ? , 1996 .

[45]  J. Carlet,et al.  INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. , 1996, Critical care medicine.

[46]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[47]  S. Willatts,et al.  Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. , 1996, Critical care medicine.

[48]  K. Werdan,et al.  Supplemental immune globulins in sepsis: a critical appraisal , 1996, Clinical and experimental immunology.

[49]  F Doyon,et al.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. , 1995, JAMA.

[50]  J. Dhainaut,et al.  CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. , 1995, Critical care medicine.

[51]  H. Bahakim,et al.  Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis , 1995, Clinical and experimental immunology.

[52]  D. Pittet,et al.  The Systemic Inflammatory Response Syndrome-Reply , 1995 .

[53]  N. MacIntyre,et al.  A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. , 1995, Critical care medicine.

[54]  E. Jones.  Prophylactic anti-lipopolysaccharide freeze-dried plasma in major burns: a double blind controlled trial. , 1995, Burns : journal of the International Society for Burn Injuries.

[55]  A. Ohlsson,et al.  Administration of intravenous immunoglobulins for prophylaxis or treatment of infection in preterm infants: meta-analyses. , 1995, Archives of disease in childhood. Fetal and neonatal edition.

[56]  J. Villar,et al.  Predictive ability of meta-analyses of randomised controlled trials , 1995, The Lancet.

[57]  S. Nasraway,et al.  Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. , 1995, JAMA.

[58]  G. Koch,et al.  Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial , 1995 .

[59]  W. Sibbald,et al.  Round table conference on clinical trials for the treatment of sepsis. , 1995, Critical care medicine.

[60]  C. Sprung,et al.  An evaluation of the hemodynamic effects of HA‐1A human monoclonal antibody , 1994, Critical care medicine.

[61]  Craig R. Smith,et al.  Treatment of Septic Shock with Human Monoclonal Antibody HA-1A , 1994, Annals of Internal Medicine.

[62]  T. Raffin,et al.  Sepsis therapy trials. Continued disappointment or reason for hope? , 1994, JAMA.

[63]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[64]  M. Z. Bakıcı,et al.  Intravenous Immunoglobulin in the Treatment of Salmonella Typhimurium Infections in Preterm Neonates , 1994, Clinical pediatrics.

[65]  S. Opal,et al.  Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial , 1994, Critical care medicine.

[66]  M. Yurdakök,et al.  The use of IgM-enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. , 1993, The Turkish journal of pediatrics.

[67]  J. Vincent,et al.  Influence of an anti‐tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis , 1993, Critical care medicine.

[68]  C. Sprung,et al.  Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. , 1992, The Journal of infectious diseases.

[69]  B. Stoll,et al.  Intravenous immune globulin therapy for early-onset sepsis in premature neonates. , 1992, The Journal of pediatrics.

[70]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[71]  N. Wedel,et al.  Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, Gram‐negative sepsis , 1992, Critical care medicine.

[72]  M. Cairo,et al.  Randomized trial of granulocyte transfusions versus intravenous immune globulin therapy for neonatal neutropenia and sepsis. , 1992, The Journal of pediatrics.

[73]  A. Rubinstein,et al.  Treatment of septic thrombocytopenia with immune globulin , 1991, Journal of Clinical Immunology.

[74]  R. Bone.  A critical evaluation of new agents for the treatment of sepsis. , 1991, JAMA.

[75]  Jerome J. Schentag,et al.  A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis , 1991 .

[76]  H. Hill,et al.  Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early-onset sepsis. , 1991, The Journal of pediatrics.

[77]  C. Sprung,et al.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .

[78]  A. Ballabio,et al.  Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. , 1991, Archives of surgery.

[79]  V. Meade,et al.  Safety of Intravenous Immunoglobulin Infusion in Neonates at Risk for Sepsis , 1990, American journal of perinatology.

[80]  M. A. Martin,et al.  Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo. , 1989, JAMA.

[81]  J. Schellekens,et al.  Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. , 1988, The Journal of infectious diseases.

[82]  H. Jesdinsky,et al.  Cooperative group of additional immunoglobulin therapy in severe bacterial infections: Results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis , 1987, Klinische Wochenschrift.

[83]  H. Just,et al.  Einfluß einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv-Therapie-Station , 1986, Klinische Wochenschrift.

[84]  Aitchison Jm,et al.  Anti-endotoxin in the treatment of severe surgical septic shock. Results of a randomized double-blind trial. , 1985 .

[85]  Y. Kobayashi,et al.  [Clinical study on SM-4300 in the field of internal medicine]. , 1985, The Japanese journal of antibiotics.

[86]  K. Matsumoto,et al.  [A clinical trial of SM-4300 against severe infections in surgery]. , 1985, The Japanese journal of antibiotics.

[87]  K. Yasunaga,et al.  [Clinical studies on the effectiveness of SM-4300, a new non-modified gammaglobulin preparation suitable for intravenous use, in refractory infections]. , 1985, The Japanese journal of antibiotics.

[88]  S. Gaffin,et al.  ANTI-LIPOPOLYSACCHARIDE IMMUNOTHERAPY IN MANAGEMENT OF SEPTIC SHOCK OF OBSTETRIC AND GYNAECOLOGICAL ORIGIN , 1984, The Lancet.

[89]  Samuel R. Wilson,et al.  Functional Antibacterial Activity of a Human Intravenous Immunoglobulin Preparation: in vitro and in vivo Studies , 1983, Vox sanguinis.

[90]  G. V. von Muralt,et al.  [Immunoglobulin substitution in the treatment of neonatal septicemia]. , 1981, Schweizerische medizinische Wochenschrift.

[91]  L. Lindquist,et al.  Pepsin‐Treated Human Gamma Globulin in Bacterial Infections: A Randomized Study in Patients with Septicaemia and Pneumonia , 1981, Vox sanguinis.

[92]  B. Hartley‐åsp.  MUTAGENICITY OF METRONIDAZOLE , 1979, The Lancet.

[93]  M. Kramer,et al.  Does one size fit all? The case for ethnic-specific standards of fetal growth , 2008 .

[94]  L. Dans,et al.  Intravenous immunoglobulin for treating sepsis and septic shock. , 2002, The Cochrane database of systematic reviews.

[95]  U. Nydegger.  Sepsis and polyspecific intravenous immunoglobulins , 1997, Journal of clinical apheresis.

[96]  A. Fein,et al.  Sepsis and multiorgan failure , 1997 .

[97]  L. Dominioni,et al.  High-dose intravenous IgG for treatment of severe surgical infections , 1996 .

[98]  I. Schedel,et al.  Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. , 1993 .

[99]  J. Mancilla-Ramirez,et al.  [Intravenous immunoglobulin in the treatment of neonatal septicemia]. , 1992, Boletin medico del Hospital Infantil de Mexico.

[100]  R. Grundmann,et al.  [Immunoglobulin therapy of postoperative sepsis]. , 1990, Zeitschrift fur experimentelle Chirurgie, Transplantation, und kunstliche Organe : Organ der Sektion Experimentelle Chirurgie der Gesellschaft fur Chirurgie der DDR.

[101]  R. Grundmann,et al.  Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis--a prospective randomized study. , 1988, Progress in clinical and biological research.

[102]  C. De Simone,et al.  Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. , 1988, Critical care medicine.